Publications by authors named "B Baugh"
Background: Modest weight and lipid changes have been observed in cabotegravir plus rilpivirine long-acting (CAB+RPV LA) Phase 3/3b studies. The SOLAR study included standardized evaluations of weight and metabolic changes in people living with HIV switching to CAB+RPV LA dosed every 2 months (Q2M) vs. continuing bictegravir/emtricitabine/tenofovir (BIC/FTC/TAF).
View Article and Find Full Text PDFArticle Synopsis
- Cabotegravir plus rilpivirine (CAB + RPV) is an effective long-acting injectable treatment for maintaining HIV-1 virologic suppression, and this analysis looked at its effects based on participants' body mass index (BMI).
- Data was collected from various trials over periods ranging from 48 to 152 weeks, focusing on virologic outcomes, confirmed failures, and safety across different BMI categories.
- Results showed similar efficacy and tolerability for CAB + RPV LA in both lower and higher BMI groups, with high rates of HIV-1 RNA suppression and comparable safety profiles.
Implementation of long-acting cabotegravir and rilpivirine: primary results from the perspective of staff study participants in the Cabotegravir And Rilpivirine Implementation Study in European Locations.
Cassidy A Gutner Laurent Hocqueloux Celia Jonsson-Oldenbüttel Linos Vandekerckhove Berend J van Welzen Bryan Baugh
J Int AIDS Soc
July 2024
Article Synopsis
- Cabotegravir plus rilpivirine (CAB+RPV) is a long-acting HIV treatment being studied for its implementation effectiveness in European clinics through the CARISEL study.
- The study involved 18 clinics that were divided into two groups: one received standard support, while the other got enhanced support that included more training and team meetings.
- Staff participants (SSPs) reported high acceptability, appropriateness, and feasibility scores for CAB+RPV throughout the year, indicating positive feedback on its implementation, with no significant differences noted between the two support groups.
Article Synopsis
- - The study examines the safety and outcomes of a long-acting HIV treatment regimen, Cabotegravir (CAB) + Rilpivirine (RPV), focusing on injection site reactions (ISRs) experienced by participants across several trials.
- - Analysis of injection techniques from healthcare providers revealed that practices such as slow injection speed and bringing the medication to room temperature helped minimize discomfort for patients during the injection process.
- - Overall, the injections showed good tolerability, with most ISRs being mild to moderate and lasting only a few days, indicating that the CAB + RPV regimen is a viable option for long-term HIV maintenance therapy.